EGFR and non-small cell lung carcinoma: Co‐mutation of TP53 in EGFR‐mutant NSCLC is reportedly associated with reduced responsiveness to first‐ or second‐generation EGFR‐TKI treatment (progression‐free survival [PFS]: 6.5 vs. 14 months, p = 0.025; OS: 28 vs. 52 months, p = 0.023) [2].